efficacy of interferon alpha- 2b with or without ribavirin in thalassemia major patients with chronic hepatitis c virus infection: a randomized, double blind, controlled, parallel group trial

Clicks: 685
ID: 201108
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 133 articles by views in 2017 ieee international conference on communication, networks and satellite, comnetsat 2017 - proceedings

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 133 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Background: The aim of this study was to evaluate the effectiveness of monotherapy with interferon alpha- 2b and combination therapy with interferon alpha- 2b plus ribavirin on chronic hepatitis C infection in thalassaemic patients. Methods: In parallel group randomized, double blind, controlled trial, 32 thalassaemic patients with chronic hepatitis C infection completed the study. In a random fashion, one group was treated with three million units of interferon alpha- 2b three times a week plus ribavirin (800- 1200 mg daily). The second group received interferon alpha- 2b alone. Treatment duration was 24- 48 weeks. Primary efficacy variables were HCV RNA after treatment and sustained viral response (SVR) six months after treatment. Results: The mean age of patients was 22 ± 7.4 years; 19 (59.4%) were male and 13 (40.6) were female. At the end of treatment, no statistically significant differences were found between the groups in HCV RNA and AST. The proportion of patients with SVR six months after treatment was significantly greater in the monotherapy group (90.9%) than in the combination therapy group (44.4%; p = 0.049). A significant difference in mean of ALT was also obtained at the end of treatment between monotherapy and combination therapy groups (30.4 ± 19.2 and 60.1 ± 48.9, respectively; p = 0.02). Response rates were not associated with genotype and severity of hepatitis C infection in both groups. Conclusions: These results suggest that monotherapy may be considered as the first- line therapy in patients with thalassemia.
Reference Key
kalantari2010journalefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Hamid Kalantari;Neda Rad
Journal 2017 ieee international conference on communication, networks and satellite, comnetsat 2017 - proceedings
Year 2010
DOI
DOI not found
URL
http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2010;volume=15;issue=6;spage=310;epage=316;aulast=Kalantari
Keywords
interferons hepacivirus ribavirin

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.